Efficacy of Jawarish Shahi a herbal formulation in irritable bowel syndrome: An open-labeled single-arm clinical trial

10.1016/j.jtcme.2022.04.004

Shehanshah Wali Moazzam；Abdul Mobeen；Mansoor Ahmad Siddiqui

Irritable bowel syndrome ； Unani medicine ； Jawarish shahi ； IBS severity Scoring scale

Journal of Traditional and Complementary Medicine

12卷6期（2022 / 11 / 01）

529 - 535

英文

Background and aim: Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders characterized by chronic recurrent abdominal pain related to a change in bowel habit or defecation frequency and commonly accompanied by anxiety and depression affecting about 10% population globally. Jawarish Shahi (JS) is a special dosage form prepared for gastrointestinal disorders in Unani medicine containing Phyllanthus emblica L., Terminalia chebula Retz., Coriandrum sativum L., Elettaria cardamomum (L.) Maton and Salix caprea L. Considering the antioxidant, immunomodulatory, antispasmodic analgesic, antidiarrheal, antisecretory, laxative, anti-inflammatory, anxiolytic, and antidepressant properties, the present study was aimed to evaluate the efficacy of JS in IBS. Experimental procedure: This single-arm open-labeled clinical trial was conducted on 26 male and female patients of IBS according to Rome IV criteria, aged 18-50 years with moderate symptoms. JS was given 7 g orally twice a day after meal with water for 45 days. IBS Severity Scoring Scale (IBS-SSS) was used for efficacy outcomes and the difference was analyzed from baseline to the subsequent follow-ups. Results: Data analysis of subsequent followup showed a significant decrease in IBS-SSS scores except for 2nd followup, scores decreased from 229.50 ± 75.91 to 203.12 ± 71.71 (p ＜ 0.1018), 150.61 ± 55.32 (p ＜ 0.0001), and 123.76 ± 54.81 (p ＜ 0.0001) at 0, 15th, 30th, 45th day of follow up respectively. Conclusion: The present study revealed that JS is safe and effective in reducing the overall symptoms of IBS in respect to its severity and impact on quality of life and can be used as an alternate as well as a complementary treatment in IBS.

1. Mani, V,Sajid, S,Rabbani, SI,Alqasir, AS,Alharbi, HA,Alshumaym, A(2021).Anxiolytic-like and antidepressant-like effects of ethanol extract of Terminalia chebula in mice.J Tradit Complementary Med,11(6),493-502.
   連結：
2. Akhtar, H,Husain, SZ(2019).A descriptive review on traditional herbal DrugTerminalia chebula.J Adv Res Biochem Pharmacol,2(1),21-28.
3. Alammar, N,Stein, E(2019).Irritable bowel syndrome: what treatments really work.Medical Clinics,103(1),137-152.
4. Al-Attar, ZI(2020).Irritable bowel syndrome: the most common presentation, severity ranking and therapeutic regimens among patients attending outpatient.L-Kindy Coll Med J.,16(1),10-17.
5. Al-Snafi, AE(2016).A review on chemical constituents and pharmacological activities of Coriandrum sativum.IOSR J Pharm,6(7),17-42.
6. An, X,Bao, Q,Di, S(2019).The interaction between the gut microbiota and herbal medicines.Biomed Pharmacother,118,109252.
7. Brandt, LJ,Chey, WD,Foxx-Orenstein, AE,Schiller, LR,Schoenfeld, PS,Spiegel, BM,Talley, NJ,Quigley, EM,American College of Gastroenterology Task Force on Irritable Bowel Syndrome(2009).An evidence-based position statement on the management of irritable bowel syndrome.The American journal of gastroenterology,104,S1-267.
8. Carco, C,Young, W,Gearry, RB,Talley, NJ,McNabb, WC,Roy, NC(2020).Increasing evidence that irritable bowel syndrome and functional gastrointestinal disorders have a microbial pathogenesis.Front Cell Infect Microbiol,10,1-24.
9. Cheng, W,Li, J,Liu, X.(2020).5-Aminosalicylic acid for treatment of irritable bowel syndrome.Medicine,99(9),e19351.
10. Colomier, E,Algera, J,Melchior, C(2021).Pharmacological therapies and their clinical targets in irritable bowel syndrome with diarrhea.Front Pharmacol,11,2464.
11. Dolan, R,Chey, WD,Eswaran, S(2018).The role of diet in the management of irritable bowel syndrome: a focus on FODMAPs.Expet Rev Gastroenterol Hepatol,12(6),60715.
12. Drossman, DA,Chang, L,Bellamy, N(2011).Severity in irritable bowel syndrome: a Rome foundation working team report.Am J Gastroenterol,106(10),1749-1759.
13. Fauci, AS,Kasper, DL,Hauser, SL,Longo, DL,Jameson, JL,Loscalzo, J.(2018).Harrison's Principles of Internal Medicine.New York:McGraw Hill education.
14. Fichna, J.1 - Introduction to irritable bowel syndrome: general overview and epidemiology.A Comprehensive Overview of Irritable Bowel Syndrome
15. Francis, CY,Morris, J,Whorwell, PJ(1997).The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress.Aliment Pharmacol Ther,11(2),395-402.
16. Gayathri, R,Aruna, T,Malar, S,Shilpa, B,Dhanasekar, KR(2020).Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome.Int J Colorectal Dis.,35(1),139-145.
17. Gu, Y,Zhou, G,Qin, X,Huang, S,Wang, B,Cao, H(2019).The potential role of gut mycobiome in irritable bowel syndrome.Front Microbiol,10
18. Heidari, B,Sajja,SE,Minaiyan, M(2016).Effect of Coriandrum sativum hydroalcoholic extract and its essential oil on acetic acid- induced acute colitis in rats.Avicenna J Phytomed,6(2),205-214.
19. Jamal, A,Javed, K,Aslam, M,Jafri, MA(2006).Gastroprotective effect of cardamom, Elettaria cardamomum Maton. fruits in rats.J Ethnopharmacol,103(2),149-153.
20. Jurenka, JS(2012).Bacillus coagulans. MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomized, double-blind, placebo controlled, multi-centre, pilot clinical study.Alternative Med Rev.,17(1),76-81.
21. Kabeeruddin, M.Bayaz Kabeer. Part-2.New Delhi:Idara Kitabul Shifa.
22. Kavuri, V,Raghuram, N,Malamud, A,Selvan, SR(2015).Irritable bowel syndrome: yoga as remedial therapy.Evid base Compl Alternative Med,1-10.
23. Khan, KH.(2009).Roles of Emblica officinalis in medicine-a review.Bot Res Int,2(4),4218-228.
24. Khan, MA,Kabeeruddin, M(Trans)(2003).Al-Akseer.New Delhi:Aijaz publishing house.
25. Kharade, SM,Gumate, DS,Patil, VM,Kokane, SP,Naikwade, NS(2011).Behavioral and biochemical studies of seeds of Coriandrum sativum in various stress models of depression.Int. J. Curr. Res. Rev.,3,4-11.
26. Lacy, BE,Pimentel, M,Brenner, DM(2021).ACG clinical guideline: management of irritable bowel syndrome.Am J Gastroenterol,116(1),17-44.
27. Mahendra, P,Bisht, S(2011).Anti-anxiety activity of Coriandrum sativum assessed using different experimental anxiety models.Indian J Pharmacol,43(5),574-577.
28. Mard, SA,Veisi, A,Naseri, MKG,Mikaili, P(2011).Spasmogenic activity of the seed of Terminalia chebula Retz in rat small intestine: in vivo and in vitro studies.Malays J Med Sci,18(3),18-26.
29. Masoumi-Ardakani, Y,Mahmoudvand, H,Mirzaei, A(2017).The effect of Elettaria cardamomum extract on anxiety-like behavior in a rat model of post-traumatic stress disorder.Biomed Pharmacother,87,489-495.
30. Mehmood, MH,Siddiqi, HS,Gilani, AH(2011).The antidiarrheal and spasmolytic activities of Phyllanthus emblica are mediated through dual blockade of muscarinic receptors and Ca2+ channels.J Ethnopharmacol,133(2),856-865.
31. Miller, LE(2014).Study design considerations for irritable bowel syndrome clinical trials.Ann Gastroenterol Quart Publ Hellenic Soc Gastroenterol,27(4),338.
32. Munjal, YP(2012).API Text Book of Medicine.Mumbai:The Association of Physicians of India.
33. Pemminati, S,Gopalakrishna, HN,Swati, B,Shreyasi, C,Pai, MR,Nair, V(2010).Anti-anxiety effect of aqueous extract of fruits of Emblica officinalis (EO) on acute and chronic administration in rats.J Pharm Res,3(2),219-233.
34. Perianayagam, JB,Narayanan, S,Gnanasekar, G(2005).Evaluation of antidiarrheal potential of Emblica officinalis.Pharm Biol,43(4),373-377.
35. Rane, SV,Asgaonkar, B,Rathi, P(2021).Effect of moderate aerobic exercises on symptoms of functional dyspepsia.Indian J Gastroenterol,40(2),189-197.
36. Saha, L(2014).Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.World J Gastroenterol,20(22),6759-6773.
37. Sengupta, A,Bhattacharjee, S(2009).Cardamom (elettaria cardamomum) and its active constituent, 1,8-cineole.Mol Targets Ther Uses Spices Mod Uses Anc Med
38. Sheng, Z,Yan, X,Zhang, R(2016).Assessment of the antidiarrhoeal properties of the aqueous extract and its soluble fractions of Chebulae Fructus (Terminalia chebula fruits).Pharm Biol,54(9),1847-1856.
39. Sperber, AD,Bangdiwala, SI,Drossman, DA(2021).Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study.Gastroenterology,160(1),99-114.
40. Suresh, K,Chandrashekara, S(2015).Sample size estimation and power analysis for clinical research studies.J Hum Reprod Sci,8,186.
41. Tarasiuk, A,Mosińska, P,Fichna, J(2018).Triphala: current applications and new per-spectives on the treatment of functional gastrointestinal disorders.Chin Med,13,39.
42. Tawfeek, N,Mahmoud, MF,Hamdan, DI(2021).Phytochemistry, pharmacology and medicinal uses of plants of the genus Salix: an updated review.Front Pharmacol,12,50.
43. Thumann, TA,Pferschy-Wenzig, EM,Moissl-Eichinger, C,Bauer, R(2019).The role of gut microbiota for the activity of medicinal plants traditionally used in the European Union for gastrointestinal disorders.J Ethnopharmacol,245,112153.
44. Tiwari, R,Pandya, DH,Baghel, MS(2013).Clinical evaluation of Bilvadileha in the management of irritable bowel syndrome.Ayu,34(4),368.
45. Trinkley, KE,Nahata, MC(2014).Medication management of irritable bowel syndrome.Digestion,89(4),253-267.
46. Vejdani, R,Shalmani, HRM,Mir-Fattahi, M(2006).The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: a pilot study.Dig Dis Sci.,51(8),1501-1507.
47. Zargaran, A,Zarshenas, MM,Hosseinkhani, A,Mehdizadeh, A(2012).Jawarish, a Persian traditional gastrointestinal dosage form.Pharm Hist,42(2),24-25.